Economic Impact of mNGS on Diagnosis of Post-neurosurgical Central Nervous System Infection (mNGS)
Central Nervous System Infections
About this trial
This is an interventional diagnostic trial for Central Nervous System Infections focused on measuring Central nervous system infections, Metagenomic next-generation sequencing
Eligibility Criteria
Inclusion Criteria: ·Central nervous system infections Exclusion Criteria: Unqualified samples Patients and their families refused to sign the informed consent The clinician considered the case unsuitable for inclusion in the study
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Experimental group
Control group
The experimental group was sent for CSF mNGS and traditional microbiological cultures at the same time, and the mNGS results were usually earlier than the traditional microbiological cultures results. The experimental group adjusted or continued the current medication regimen according to the mNGS reporting pathogen and the expert team's opinion. Subsequently, if the CSF traditional microbiological cultures results in the experimental group are consistent with the mNGS results, the current treatment plan of the patient is continued, and if the results are inconsistent with the mNGS results, the expert team needs to discuss and adjust the treatment plan. When no causative organism is detected in mNGS, empiric treatment is continued, and treatment is adjusted pending the pathogen culture results.
After a clinical diagnosis of central nervous system infection, the control group was treated empirically based on only cerebrospinal fluid for traditional microbiological cultures, without mNGS detection, and the treatment plan was adjusted according to the traditional microbiological cultures results. If the patient's culture is negative and empiric therapy does not improve, cerebrospinal fluid is retained for mNGS testing. Treatment is adjusted based on mNGS results and expert team evaluation.